These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 30056768)

  • 1. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Miura Y; Lefor AK; Yamamoto H
    Kaohsiung J Med Sci; 2017 Dec; 33(12):616-622. PubMed ID: 29132551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
    Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease.
    Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K
    Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor-resistant gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Miura Y; Lefor AK; Yamamoto H
    Biomed Rep; 2021 Mar; 14(3):32. PubMed ID: 33585034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease.
    Gotoh Y; Ishibashi E; Honda S; Nakaya T; Noguchi C; Kagawa K; Murakami K
    Medicine (Baltimore); 2020 Mar; 99(11):e19520. PubMed ID: 32176102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
    Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
    Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
    Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
    Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Kobayashi Y; Lefor AK; Yamamoto H
    Biomed Rep; 2017 Sep; 7(3):231-235. PubMed ID: 28894571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
    Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
    Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: A systematic review and meta-analysis.
    Bandyopadhyay S; Verma P; Samajdar SS; Das S
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102373. PubMed ID: 38719148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of hiatal hernia is a significant predictor for symptomatic recurrence after cessation of vonoprazan therapy for gastroesophageal reflux disease: a long-term observational study.
    Shinozaki S; Osawa H; Miura Y; Sakamoto H; Hayashi Y; Yano T; Despott EJ; Yamamoto H
    Scand J Gastroenterol; 2024 Aug; 59(8):893-899. PubMed ID: 38821110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
    Simadibrata DM; Lesmana E; Fass R
    J Gastroenterol Hepatol; 2024 May; 39(5):796-805. PubMed ID: 38263507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences Between Patients with Heartburn Refractory to Vonoprazan and Those Refractory to Proton Pump Inhibitors.
    Matsumura T; Sonoda M; Okimoto K; Dao HV; Takahashi S; Akizue N; Horio R; Goto C; Kurosugi A; Kaneko T; Ohta Y; Taida T; Kikuchi A; Fujie M; Kato J; Kato N
    Dig Dis Sci; 2024 Jun; 69(6):2132-2139. PubMed ID: 38622462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.
    Miwa H; Igarashi A; Teng L; Uda A; Deguchi H; Tango T
    J Gastroenterol; 2019 Aug; 54(8):718-729. PubMed ID: 30919071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
    Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
    Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
    Hamada S; Ihara E; Ikeda H; Muta K; Ogino H; Chinen T; Tanaka Y; Ogawa Y
    Digestion; 2021; 102(2):197-204. PubMed ID: 31578027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021.
    Iwakiri K; Fujiwara Y; Manabe N; Ihara E; Kuribayashi S; Akiyama J; Kondo T; Yamashita H; Ishimura N; Kitasako Y; Iijima K; Koike T; Omura N; Nomura T; Kawamura O; Ohara S; Ozawa S; Kinoshita Y; Mochida S; Enomoto N; Shimosegawa T; Koike K
    J Gastroenterol; 2022 Apr; 57(4):267-285. PubMed ID: 35226174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.